Furthermore, these findings suggest potential therapeutic avenues, as modulation of metabolic pathways—via GLP-1 receptor agonists, dual incretin receptor agonists (twincretins), or anti-inflammatory interventions—may alter EAT composition and function, leading to improved metabolic efficiency, attenuation of adipose inflammation, and favorable cardiovascular effects. The gene discussed is GLP1R; the disease is inflammation.